Evidence map›Paper›PMID 37938322›Full record

ArticleVirchows Archiv : an international journal of pathology2024

Prognostic value of HPV-PCR, p16 and p53 immunohistochemical status on local recurrence rate and survival in patients with vulvar squamous cell carcinoma.

A W Pouwer, N C Te Grootenhuis, F Hinten, G H de Bock, A G J van der Zee, W J G Melchers, M H M Oonk, J A de Hullu, H Hollema, J Bulten

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virchows Archiv : an international journal of pathology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

A W PouwerDepartment of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
N C Te GrootenhuisDepartment of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands. n.c.te.grootenhuis@umcg.nl.ORCID http://orcid.org/0000-0001-7488-7095
F HintenDepartment of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
G H de BockDepartment of Epidemiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
A G J van der ZeeDepartment of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
W J G MelchersDepartment of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands.
M H M OonkDepartment of Obstetrics and Gynaecology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J A de HulluDepartment of Obstetrics and Gynaecology, Radboud University Medical Center, Nijmegen, The Netherlands.
H HollemaDepartment of Pathology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J BultenDepartment of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The primary aim of this study was to assess the association between human papilloma virus (HPV) and p53 expression and local recurrence (LR), disease specific survival (DSS), and overall survival (OS) in patients with vulvar squamous cell carcinoma (VSCC). Secondary, the accuracy of p16 immunohistochemistry for HPV status was assessed. The tumor tissue of 255 patients, surgically treated for primary unifocal VSCC between 2000 and 2010, was analyzed. HPV-PCR and P16 and p53 immunohistochemical stainings were performed. All histologic slides were independently reviewed by two expert gyneco-pathologists. Time to first LR, DSS, and OS for the variables p16, p53, and HPV-PCR were compared using univariable and multivariable Cox-regression analyses. In 211/255 (83.5%) patients, HPV-PCR was negative. The local recurrence rate was significantly lower in patients positive with HPV-PCR (10-year LR rate 24.6%) versus negative tumors (47.5%), p = 0.004. After multivariable analyses, this difference remained significant (HR 0.23 (95% CI 0.08-0.62) p = 0.004). There was no difference in LR rate correlated to the p53 expression. DSS and OS did not significantly differ after multivariable analyses for all different subgroups. Sensitivity and specificity of p16 staining for presence of HPV detected by HPV-PCR were 86.4% and 93.8%, respectively. In conclusion, patients with HPV-negative VSCCs have significantly more LR compared to patients with HPV-positive VSCCs, and p16 immunohistochemistry is a reliable surrogate marker for HPV status. No relevant subgroup for LR or survival based on HPV/p53 status could be identified. We advise to perform an HPV-PCR or p16 IHC staining in all patients with VSCC.

Indexed as

Biomarkers, TumorCarcinoma, Squamous CellCyclin-Dependent Kinase Inhibitor p16ImmunohistochemistryNeoplasm Recurrence, LocalPapillomavirus InfectionsTumor Suppressor Protein p53Vulvar NeoplasmsAdultAgedAged, 80 and overFemaleHumansMiddle AgedPapillomaviridaePolymerase Chain ReactionBiomarkers, TumorCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16TP53 protein, humanTumor Suppressor Protein p53HPVLocal recurrencep16p53SurvivalVulvar carcinoma

Identifiers

PMID37938322
PMCPMC11186908

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.